DDInter596 DDInter703
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of adult HIV-1 infection documented to be resistant to therapy with other NNRTIs and antiretroviral agents. On March 26, 2012, approval was extended for use in treatment-experienced pediatric patients 6 to 18 years of age, weighing at least 16 kg. Etravarine must always be used in combination with other antiretroviral drugs. Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-1), and consequently blocks DNA-dependent and RNA-dependent polymerase activity. Etravirine does not inhibit human DNA polymerase alpha, beta or gamma. Common side effects of use include mild to moderate rash within the first 6 weeks of therapy, nausea, diarrhea and peripheral neuropathy. Patients are advised to immediately contact their healthcare provider if a rash develops. In 2009, postmarketing case reports of Stevens-Johnson Syndrome, toxic epidermal necrolysis, erythema multiforme, and other hypersensitivity reactions lead to a revision of etravirine's "Warnings and Precautions," as well as notification of health care providers. In 2013, reports of Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) in the setting of immune reconstitution, as well as more in depth information about the development of rashes in patients taking etravirine, lead to a modification of etravirine's monograph.
Doxorubicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Etravirine
Doxorubicin {u} (Compound) causes {v} (Side Effect) Malnutrition
Malnutrition {u} (Side Effect) is caused by {v} (Compound) Etravirine
Doxorubicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Rilpivirine
Rilpivirine {u} (Compound) resembles {v} (Compound) Etravirine
Doxorubicin {u} (Compound) causes {v} (Side Effect) Malnutrition
Malnutrition {u} (Side Effect) is caused by {v} (Compound) Rilpivirine
Rilpivirine {u} (Compound) resembles {v} (Compound) Etravirine
Doxorubicin {u} (Compound) causes {v} (Side Effect) Haematemesis
Haematemesis {u} (Side Effect) is caused by {v} (Compound) Ranitidine
Ranitidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Etravirine
Doxorubicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Ranitidine
Ranitidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Etravirine
Doxorubicin {u} (Compound) causes {v} (Side Effect) Blister
Blister {u} (Side Effect) is caused by {v} (Compound) Sunitinib
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etravirine
Doxorubicin {u} (Compound) causes {v} (Side Effect) Drug hypersensitivity
Drug hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Apixaban
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etravirine
Doxorubicin {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Sunitinib
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etravirine
Doxorubicin {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Apixaban
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etravirine
Doxorubicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Etravirine (Compound)
Doxorubicin (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Etravirine (Compound)
Doxorubicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Rilpivirine (Compound) and Rilpivirine (Compound) resembles Etravirine (Compound)
Doxorubicin (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Rilpivirine (Compound) and Rilpivirine (Compound) resembles Etravirine (Compound)
Doxorubicin (Compound) causes Haematemesis (Side Effect) and Haematemesis (Side Effect) is caused by Ranitidine (Compound) and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Etravirine
Doxorubicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ranitidine (Compound) and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Etravirine
Doxorubicin (Compound) causes Blister (Side Effect) and Blister (Side Effect) is caused by Sunitinib (Compound) and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Doxorubicin (Compound) causes Drug hypersensitivity (Side Effect) and Drug hypersensitivity (Side Effect) is caused by Apixaban (Compound) and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Doxorubicin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Sunitinib (Compound) and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Doxorubicin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Apixaban (Compound) and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Etravirine